Form 4: Theravance Biopharma Executive Sells 4,000 Shares Under 10b5-1 Plan

Rhonda Farnum, SVP at Theravance Biopharma, sold 4,000 ordinary shares at $9 each, as part of a pre-arranged 10b5-1 trading plan.

Summary

• Rhonda Farnum, a Senior Vice President at Theravance Biopharma, sold 4,000 ordinary shares of the company.
• The sale occurred on January 21, 2025, at a price of $9 per share.
• This transaction was executed under a pre-existing 10b5-1 trading plan established on March 14, 2024.
• Following the sale, Ms. Farnum beneficially owns 309,565 ordinary shares.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction under a pre-arranged plan, with no indication of positive or negative sentiment. It is a neutral event.

Risks

• Executive stock sales can sometimes be perceived negatively by the market, although this sale was pre-planned.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies, and the use of 10b5-1 plans is a standard practice to avoid accusations of insider trading. This transaction is not unusual and is part of a pre-arranged plan.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, including those in the biotechnology sector like Amgen, Gilead Sciences, and Biogen.
• These plans allow executives to sell shares at predetermined times and prices, mitigating the risk of insider trading allegations.
• The volume of shares sold by Ms. Farnum is relatively small compared to the total outstanding shares of Theravance Biopharma, and is not unusual for an executive sale.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on shareholder sentiment, but the pre-planned nature of the transaction mitigates this.

Key Dates

Keywords

Theravance Biopharma, insider trading, stock sale, Form 4, 10b5-1 plan, executive, share transaction